Alphamab Oncology (Stock Code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 has ...

Zenocutuzumab helps fill an important need for patients with advanced pancreatic cancer and NSCLC with NRG1 gene fusions, said Alison Schram M.D., ...

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on February 4, 2025, the Compensation ...

The publication reviews the results of 204 patients with 12 tumor types enrolled and treated on the eNRGy study, concluding “Zenocutuzumab demonstrated durable efficacy in patients with advanced NRG1+ ...

Published in Cell Reports Medicine, results of a VHIO-led study support the feasibility of using RAD51 testing to complement ...

Researchers report that all nine patients in a clinical trial being treated for stage III or IV clear cell renal cell carcinoma (a form of kidney cancer), generated a successful anti-cancer immune ...

The lab of The Wistar Institute's Jessie Villanueva, Ph.D., has identified a new strategy for attacking treatment-resistant ...

The researchers found that imlunestrant prolonged progression-free survival (PFS) when compared to standard care in patients with ESR1 mutations, but there was no PFS benefit observed in the overall ...

The PATHWAY HER2 (4B5) test is now FDA-approved to assess HER2-ultralow status in metastatic breast cancer, expanding its ...

Nearly 60,000 people are diagnosed with oral cancer in the U.S. every year, according to the American Cancer Society, and the rate of new cases continues to rise.

Every cell in the body normally has its fixed place as part of a tissue structure. Except for a few cell types, such as blood ...

Collaboration focuses on launching an AI-powered biomarker prediction panel targeting actionable biomarkers to revolutionize lung cancer diagnostics and enable commercialization of a diagnostic panel.